The children were randomly allocated to one of two treatment groups. The first took budesonide 200 ,ug twice daily and placebo BDP four times daily for one month, followed by placebo budesonide twice daily and BDP 100 Cug four times daily for a further month. In the second group the order was reversed. The BDP was administered in the same form as used by the child before the trial. The budesonide was administered by pressurised aerosol with a spacer inhaler. All children were judged to use their inhalers adequately.
Of the 27 children completing the study, 15 used the pressurised aerosol and 12 the rotahaler preparation of BDP. There were no significant differences in any evaluation between these two modes of delivery during the trial, and the results were therefore assessed together.
The FEV1, FVC, PEFR, Vmax5O, and Vmax25 measured at the end of each month showed no significant differences. The morning and evening PEFRs and diary card symptom scores for the second 2 weeks of each month were ccmpared and differences did not reach significant levels (Figure) , although there was a consistent tendency towards greater benefit from budesonide (Table) . Analyses took treatment order into account, and there was no significant difference between any 2-week period throughout the trial.
All the routine blood tests were normal apart from an eosinophilia (>0 5 x 109/l) in 15 patients. There was no significant change in any parameter by the end of the trial. None of the basal cortisol levels measured at the beginning and end of the trial was subnormal (< 150 nmol /1). Plasma cortisol responses to Synacthen did not alter significantly after drug treatment in either treatment group. There were 18 normal responses on both occasions (increase> 190 nmol/l); 5 marginally subnormal responses at the beginning of the trial, but normal at the end; 3 nornal on the first occasion, but not repeated; and I child with a subnormal response at the end of the study (basal 500 increasing to 600 nmol/l). For the purposes of the trial the dose of BDP was doubled in 12 of the children; 8 of these showed an improvement in the flow volume curves while on the higher dose. 
